Koers Reviva Pharmaceuticals Holdings, Inc. Nasdaq
Aandelen
TZAC
US76152G1004
Biotechnologie & Medisch Onderzoek
Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,35 USD | -72,78% | -10,14% | -43,28% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 36,43 mln. 33,63 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -37 mln. -34,15 mln. | Nettowinst (verlies) 2025 * | -43 mln. -39,69 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 39,9 mln. 36,82 mln. | Nettoliquiditeiten 2025 * | 31,9 mln. 29,44 mln. | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-1,05
x | K/w-verhouding 2025 * |
-0,99
x | Werknemers | 15 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 82,29% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 59 | 11-12-20 | |
Narayan Prabhu
DFI | Director of Finance/CFO | 53 | 14-12-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 69 | 14-12-20 | |
Les Funtleyder
BRD | Director/Board Member | 54 | 14-12-20 |
Founder | 59 | 11-12-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+54,21% | 55,07 mld. | |
-1,65% | 41,79 mld. | |
+45,32% | 40,22 mld. | |
-7,59% | 28,17 mld. | |
+12,31% | 26,28 mld. | |
-21,11% | 18,93 mld. | |
+7,34% | 13,03 mld. | |
+29,73% | 12,26 mld. | |
+26,65% | 12,21 mld. |
- Beurs
- Aandelen
- Koers RVPH
- Koers TZAC